IL109982A - תכשירי רוקחות המכילים איזובלראמיד ושיטות להכנתם - Google Patents
תכשירי רוקחות המכילים איזובלראמיד ושיטות להכנתםInfo
- Publication number
- IL109982A IL109982A IL10998294A IL10998294A IL109982A IL 109982 A IL109982 A IL 109982A IL 10998294 A IL10998294 A IL 10998294A IL 10998294 A IL10998294 A IL 10998294A IL 109982 A IL109982 A IL 109982A
- Authority
- IL
- Israel
- Prior art keywords
- isovaleramide
- anxiolytic
- sedative
- activity
- subject
- Prior art date
Links
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 title claims abstract description 105
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 7
- 230000000949 anxiolytic effect Effects 0.000 claims abstract description 42
- 241001465754 Metazoa Species 0.000 claims description 34
- 230000007958 sleep Effects 0.000 claims description 16
- 208000019901 Anxiety disease Diseases 0.000 claims description 11
- 230000036506 anxiety Effects 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 6
- 206010039897 Sedation Diseases 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 230000036280 sedation Effects 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 3
- 206010001497 Agitation Diseases 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 206010056344 Menstrual discomfort Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- 230000005586 smoking cessation Effects 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 231100000736 substance abuse Toxicity 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 abstract description 35
- 239000002249 anxiolytic agent Substances 0.000 abstract description 28
- 239000000932 sedative agent Substances 0.000 abstract description 26
- 210000003169 central nervous system Anatomy 0.000 abstract description 13
- 231100000065 noncytotoxic Toxicity 0.000 abstract description 2
- 230000002020 noncytotoxic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 33
- 238000012360 testing method Methods 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- QRCJOCOSPZMDJY-UHFFFAOYSA-N valnoctamide Chemical compound CCC(C)C(CC)C(N)=O QRCJOCOSPZMDJY-UHFFFAOYSA-N 0.000 description 24
- 229960001364 valnoctamide Drugs 0.000 description 24
- 230000000147 hypnotic effect Effects 0.000 description 22
- 239000000126 substance Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- 238000010171 animal model Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229940125723 sedative agent Drugs 0.000 description 11
- 230000006742 locomotor activity Effects 0.000 description 10
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 10
- 244000126014 Valeriana officinalis Species 0.000 description 9
- 235000013832 Valeriana officinalis Nutrition 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229940125717 barbiturate Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000016788 valerian Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000035939 shock Effects 0.000 description 7
- FWKBQAVMKVZEOT-STCFVSJZSA-N Acevaltrate Chemical compound C([C@]12[C@@H](OC(=O)CC(C)(C)OC(C)=O)C=C3C(COC(C)=O)=CO[C@H]([C@H]23)OC(=O)CC(C)C)O1 FWKBQAVMKVZEOT-STCFVSJZSA-N 0.000 description 6
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 6
- 239000003179 convulsant agent Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229960001412 pentobarbital Drugs 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229930003658 monoterpene Natural products 0.000 description 5
- 150000002773 monoterpene derivatives Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 230000021824 exploration behavior Effects 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 3
- WQKBMPNNRRZQLG-UHFFFAOYSA-N Acevaltratum Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)(C)OC(C)=O)COC(C)=O)C2C11CO1 WQKBMPNNRRZQLG-UHFFFAOYSA-N 0.000 description 3
- PHHROXLDZHUIGO-PNBTUHDLSA-N Didrovaltratum Chemical compound C([C@@]12[C@@H](OC(C)=O)C[C@H]3[C@@H]1[C@H](OC(=O)CC(C)C)OC=C3COC(=O)CC(C)C)O2 PHHROXLDZHUIGO-PNBTUHDLSA-N 0.000 description 3
- KQEOKUJOWVGWDX-UHFFFAOYSA-N Isodihydrovaltrate Natural products CC(C)CC(=O)OC1CC(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 KQEOKUJOWVGWDX-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- FWKBQAVMKVZEOT-UHFFFAOYSA-N acevaltrat Natural products C12C(OC(=O)CC(C)C)OC=C(COC(C)=O)C2=CC(OC(=O)CC(C)(C)OC(C)=O)C21CO2 FWKBQAVMKVZEOT-UHFFFAOYSA-N 0.000 description 3
- 229950005206 acevaltrate Drugs 0.000 description 3
- 230000000338 anxiogenic effect Effects 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- -1 diazepam ("VALIUM") Chemical class 0.000 description 3
- 229950005934 didrovaltrate Drugs 0.000 description 3
- PVKOJQHHDYMUEI-UHFFFAOYSA-N didrovaltrate Natural products CC(C)CC(=O)COC1=COC(OC(=O)CC(C)C)C2C1CC(OC(=O)C)C23CO3 PVKOJQHHDYMUEI-UHFFFAOYSA-N 0.000 description 3
- PHHROXLDZHUIGO-UHFFFAOYSA-N dihydrovaltrate Natural products CC(C)CC(=O)OCC1=COC(OC(=O)CC(C)C)C2C1CC(OC(C)=O)C21CO1 PHHROXLDZHUIGO-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000005554 hypnotics and sedatives Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229950008559 valtrate Drugs 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010013142 Disinhibition Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000010275 acute porphyria Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 208000033552 hepatic porphyria Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940068146 valepotriate Drugs 0.000 description 2
- 229940072690 valium Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 229940072698 ativan Drugs 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- QZMQDHNCNUGQSO-UHFFFAOYSA-N isovaleryl diethylamide Chemical compound CCN(CC)C(=O)CC(C)C QZMQDHNCNUGQSO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
- 229960001930 valpromide Drugs 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/075,126 US5506268A (en) | 1993-06-11 | 1993-06-11 | Use of isovaleramide as a mild anxiolytic and sedative agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL109982A0 IL109982A0 (en) | 1994-10-07 |
| IL109982A true IL109982A (he) | 1998-09-24 |
Family
ID=22123718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10998294A IL109982A (he) | 1993-06-11 | 1994-06-10 | תכשירי רוקחות המכילים איזובלראמיד ושיטות להכנתם |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5506268A (he) |
| EP (1) | EP0706385B1 (he) |
| JP (2) | JP3790267B2 (he) |
| KR (1) | KR100341993B1 (he) |
| CN (1) | CN1108793C (he) |
| AT (1) | ATE213630T1 (he) |
| CA (1) | CA2164842C (he) |
| DE (1) | DE69429990T2 (he) |
| DK (1) | DK0706385T3 (he) |
| ES (1) | ES2170770T3 (he) |
| IL (1) | IL109982A (he) |
| PT (1) | PT706385E (he) |
| RU (1) | RU2136271C1 (he) |
| TW (1) | TW420606B (he) |
| WO (1) | WO1994028888A1 (he) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4113984C2 (de) * | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
| US5786382A (en) * | 1995-11-03 | 1998-07-28 | Childers-Zadah; Vsande | Use of valerian plant and/or root as a scent-attractant for stimulating canines and felines |
| DK0938304T3 (da) * | 1996-08-30 | 2005-03-14 | Nps Pharma Inc | Isovaleramid til behandlingen af kramper, epilepsi, hovedpine og spasticitet |
| US6589994B1 (en) * | 1996-08-30 | 2003-07-08 | Nps Pharmaceuticals, Inc. | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound |
| IL120006A (en) * | 1997-01-14 | 2000-12-06 | Yissum Res Dev Co | Valnoctamide stereoisomers and a method for their synthesis and separation |
| ATE309200T1 (de) | 1997-12-10 | 2005-11-15 | Nps Pharma Inc | Antikonvulsive und zns-aktive bis-fluoralkylamide |
| EP1576962A1 (en) * | 1998-03-04 | 2005-09-21 | Nps Pharmaceuticals, Inc. | Composition comprising isovaleramide and ibuprofen |
| ATE295160T1 (de) * | 1998-03-04 | 2005-05-15 | Nps Pharma Inc | Zusammensetzungen enthaltend isovalerianamide zusammen mit ibuprofen |
| US6383527B1 (en) * | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
| US6346283B1 (en) | 1999-03-26 | 2002-02-12 | Ancile Pharmaceuticals | Use of valeriana for the treatment of restless leg syndrome and related disorders |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| RU2199309C1 (ru) * | 2001-12-29 | 2003-02-27 | Закрытое акционерное общество "Брынцалов-А" | Лекарственное средство нобрассит седативного и анксиолитического действия |
| RU2209062C1 (ru) * | 2002-03-19 | 2003-07-27 | Институт физиологии им. И.П.Павлова РАН | Вещество, обладающее седативным действием |
| CA2487849A1 (en) | 2002-07-18 | 2004-01-29 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| WO2006012603A2 (en) * | 2004-07-22 | 2006-02-02 | Nps Pharmaceuticals, Inc. | Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| US20210130285A1 (en) | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| US9212155B2 (en) | 2008-03-19 | 2015-12-15 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| US10793515B2 (en) | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| KR102222910B1 (ko) | 2019-04-30 | 2021-03-04 | 차은정 | 평상형 원목침대 |
| KR102227555B1 (ko) | 2019-12-24 | 2021-03-15 | 주식회사 리빙테크 | 황토볼이 구비된 편백나무 침대 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4205083A (en) * | 1968-03-30 | 1980-05-27 | Kali-Chemie Aktiengesellschaft | Cyclopentapyrans |
| FR2306687A2 (fr) * | 1975-04-08 | 1976-11-05 | Buzas Andre | Derives d'acides phenoxy-acetiques, leur preparation et leur application en therapeutique |
| FR2209555B1 (he) * | 1972-12-11 | 1975-11-28 | Labaz | |
| SU668261A1 (ru) * | 1977-03-21 | 1985-03-15 | Киевский научно-исследовательский институт фармакологии и токсикологии | @ -Алкил- @ -( @ -оксифенил)-амиды 3,4,5-триметоксибензойной кислоты,обладающие нейролептической активностью |
| US4246282A (en) * | 1979-06-07 | 1981-01-20 | Labaz | ω-Dialkylalkanoic acid derivatives used to induce antianoxic activity |
| DE3026579A1 (de) * | 1980-07-14 | 1982-02-11 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 2,9-dioxatricyclo (4,3,1,o(pfeil hoch)3,7(pfeil hoch)) decane |
| US4814183A (en) * | 1987-08-31 | 1989-03-21 | Merck & Co., Inc. | Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins |
| FR2648814B1 (fr) * | 1989-06-26 | 1991-10-18 | Lafon Labor | L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique |
| DE4008403A1 (de) * | 1990-03-16 | 1991-09-19 | Merck Patent Gmbh | Glykolsaeurederivate |
| FR2674524B1 (fr) * | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
-
1993
- 1993-06-11 US US08/075,126 patent/US5506268A/en not_active Expired - Lifetime
-
1994
- 1994-06-10 RU RU96102019A patent/RU2136271C1/ru not_active IP Right Cessation
- 1994-06-10 PT PT94920093T patent/PT706385E/pt unknown
- 1994-06-10 JP JP50202095A patent/JP3790267B2/ja not_active Expired - Fee Related
- 1994-06-10 EP EP94920093A patent/EP0706385B1/en not_active Expired - Lifetime
- 1994-06-10 DE DE69429990T patent/DE69429990T2/de not_active Expired - Fee Related
- 1994-06-10 KR KR1019950705615A patent/KR100341993B1/ko not_active Expired - Fee Related
- 1994-06-10 WO PCT/US1994/006356 patent/WO1994028888A1/en not_active Ceased
- 1994-06-10 AT AT94920093T patent/ATE213630T1/de not_active IP Right Cessation
- 1994-06-10 ES ES94920093T patent/ES2170770T3/es not_active Expired - Lifetime
- 1994-06-10 CA CA002164842A patent/CA2164842C/en not_active Expired - Fee Related
- 1994-06-10 IL IL10998294A patent/IL109982A/he not_active IP Right Cessation
- 1994-06-10 CN CN94192865A patent/CN1108793C/zh not_active Expired - Fee Related
- 1994-06-10 DK DK94920093T patent/DK0706385T3/da active
- 1994-06-11 TW TW083105347A patent/TW420606B/zh not_active IP Right Cessation
-
1996
- 1996-03-29 US US08/623,691 patent/US5763494A/en not_active Expired - Fee Related
-
2006
- 2006-02-03 JP JP2006026874A patent/JP2006169259A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL109982A0 (en) | 1994-10-07 |
| AU701360B2 (en) | 1999-01-28 |
| KR100341993B1 (ko) | 2002-11-29 |
| CN1127472A (zh) | 1996-07-24 |
| CA2164842C (en) | 2006-08-29 |
| EP0706385A1 (en) | 1996-04-17 |
| RU2136271C1 (ru) | 1999-09-10 |
| TW420606B (en) | 2001-02-01 |
| JP2006169259A (ja) | 2006-06-29 |
| US5763494A (en) | 1998-06-09 |
| JPH09501908A (ja) | 1997-02-25 |
| ES2170770T3 (es) | 2002-08-16 |
| DE69429990T2 (de) | 2002-09-05 |
| EP0706385B1 (en) | 2002-02-27 |
| DK0706385T3 (da) | 2002-04-29 |
| WO1994028888A1 (en) | 1994-12-22 |
| PT706385E (pt) | 2002-07-31 |
| JP3790267B2 (ja) | 2006-06-28 |
| US5506268A (en) | 1996-04-09 |
| ATE213630T1 (de) | 2002-03-15 |
| DE69429990D1 (de) | 2002-04-04 |
| AU7100694A (en) | 1995-01-03 |
| CN1108793C (zh) | 2003-05-21 |
| CA2164842A1 (en) | 1994-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0706385B1 (en) | Use of isovaleramide as a mild anxiolytic and mild sedative agent | |
| Herbert et al. | Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C | |
| Iwu et al. | Evaluation of the antihepatotoxic activity of the biflavonoids of Garcinia kola seed | |
| Simiand et al. | The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents | |
| Boulenger et al. | Chronic caffeine consumption increases the number of brain adenosine receptors | |
| Davies et al. | Halogenated pyrrolopyrimidine analogues of adenosine from marine organisms: pharmacological activities and potent inhibition of adenosine kinase | |
| Taïwe et al. | Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents | |
| N'gouemo et al. | Effects of ethanol extract of Annona muricata on pentylenetetrazol‐induced convulsive seizures in mice | |
| Griffiths et al. | Caffeine reinforcement, discrimination, tolerance and physical dependence in laboratory animals and humans | |
| Helal et al. | Effect of some food colorants (synthetic andNatural products) of young albino rats | |
| Gill et al. | Effects of serotonin uptake blockade on food, water, and ethanol consumption in rats | |
| Myers et al. | Effects of serotonin depletion on the volitional alcohol intake of rats during a condition of psychological stress | |
| NZ264506A (en) | Use of (s)-(-)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide in anxiolytic treatment | |
| Badishtov et al. | To drink or not to drink: open field behavior in alcohol-preferring and-nonpreferring rat strains | |
| Mistlberger et al. | Ethanol and circadian rhythms in the Syrian hamster: effects on entrained phase, reentrainment rate, and period | |
| Bruhwyler et al. | Clozapine: an atypical neuroleptic | |
| Durbin et al. | Pharmacodynamics and pharmacokinetics of acamprosate: an overview | |
| AU701360C (en) | Use of isovaleramide as a mild anxiolytic and mild sedative agent | |
| Bhattamisra et al. | Anxiolytic activity of Marsilea minuta Linn in rodents | |
| Buchbauer et al. | R‐(+)‐and S‐(−)‐carvone: influence of chirality on locomotion activity in mice | |
| Al-Hachim | Teratogenicity of caffeine; a review | |
| Tampier et al. | Genetic differences in tolerance to ethanol: A study in UChA and UChB rats | |
| RU2104024C1 (ru) | Сбор "касмин" для профилактики и лечения тромбозов | |
| De Smet et al. | Drugs used in non-orthodox medicine | |
| Parker et al. | The effects of ethanol on cerebral regional acetylcholine concentration and utilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |